Anna Czarna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7692508/publications.pdf

Version: 2024-02-01

		471477	501174
26	1,581	17	28
papers	citations	h-index	g-index

31	31	31	2247
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses. Cell Chemical Biology, 2022, 29, 774-784.e8.	5.2	34
2	Mechanism of MyD88S mediated signal termination. Cell Communication and Signaling, 2022, 20, 10.	6.5	6
3	Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe. Pharmaceuticals, 2022, 15, 697.	3.8	7
4	Characterization of SARS-CoV-2 replication complex elongation and proofreading activity. Scientific Reports, 2022, 12, .	3.3	9
5	Rational designs of in vivo CRISPR-Cas delivery systems. Advanced Drug Delivery Reviews, 2021, 168, 3-29.	13.7	125
6	Diabetic Kinome Inhibitorsâ€"A New Opportunity for Î²-Cells Restoration. International Journal of Molecular Sciences, 2021, 22, 9083.	4.1	9
7	DYRK1A Kinase Inhibitors Promote Î²-Cell Survival and Insulin Homeostasis. Cells, 2021, 10, 2263.	4.1	8
8	An All-in-One Nanomedicine Consisting of CRISPR-Cas9 and an Autoantigen Peptide for Restoring Specific Immune Tolerance. ACS Applied Materials & Interfaces, 2020, 12, 48259-48271.	8.0	24
9	Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 7560-7572.	6.4	26
10	Function of C-terminal peptides on enzymatic and interfacial adsorption properties of lipase from Gibberella zeae. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2623-2631.	2.4	3
11	p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo. EBioMedicine, 2017, 16, 224-237.	6.1	9
12	Single-cell analysis of the fate of c-kit-positive bone marrow cells. Npj Regenerative Medicine, 2017, 2, 27.	5.2	14
13	Staphylococcal SplB Serine Protease Utilizes a Novel Molecular Mechanism of Activation. Journal of Biological Chemistry, 2014, 289, 15544-15553.	3.4	17
14	c-Kitâ€"Positive Cardiac Stem Cells Nested in Hypoxic Niches Are Activated by Stem Cell Factor Reversing the Aging Myopathy. Circulation Research, 2014, 114, 41-55.	4.5	87
15	Structures of Drosophila Cryptochrome and Mouse Cryptochrome1 Provide Insight into Circadian Function. Cell, 2013, 153, 1394-1405.	28.9	177
16	Quantitative Analyses of Cryptochrome-mBMAL1 Interactions. Journal of Biological Chemistry, 2011, 286, 22414-22425.	3.4	41
17	Robust Generation of Lead Compounds for Proteinâ€"Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists. Angewandte Chemie - International Edition, 2010, 49, 5352-5356.	13.8	136
18	Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle, 2010, 9, 1104-1111.	2.6	217

#	Article	IF	Citations
19	High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle, 2009, 8, 1176-1184.	2.6	98
20	Rapid and Efficient Hydrophilicity Tuning of p53/mdm2 Antagonists. ACS Combinatorial Science, 2009, 11, 631-639.	3.3	34
21	Isoquinolinâ€1â€one Inhibitors of the MDM2â€“p53 Interaction. ChemMedChem, 2008, 3, 1118-1128.	3.2	51
22	Enzymatic Activity of the Staphylococcus aureus SplB Serine Protease is Induced by Substrates Containing the Sequence Trp-Glu-Leu-Gln. Journal of Molecular Biology, 2008, 379, 343-356.	4.2	43
23	NMR Screening for Lead Compounds Using Tryptophan-Mutated Proteins. Journal of Medicinal Chemistry, 2008, 51, 5035-5042.	6.4	12
24	Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle, 2008, 7, 2441-2443.	2.6	182
25	Molecular Basis for the Inhibition of p53 by Mdmx. Cell Cycle, 2007, 6, 2386-2392.	2.6	132
26	Functional and Structural Characterization of Spl Proteases from Staphylococcus aureus. Journal of Molecular Biology, 2006, 358, 270-279.	4.2	47